Tevogen Bio Holdings shares rise 10.26% premarket as analysts expect breakeven by 2027.
ByAinvest
Friday, Jan 9, 2026 7:26 am ET1min read
TVGN--
Tevogen Bio Holdings (NASDAQ:TVGN) rose 10.26% in premarket trading amid analyst-driven optimism about its path to breakeven. Recent analysis from Simply Wall St highlighted expectations for the company to turn a $259 million profit in 2027, following a projected final loss in 2026, implying a 52% annual growth rate. While the firm currently reports a $31 million trailing-twelve-month loss and negative equity, the anticipated turnaround—despite being optimistic—signals potential investor confidence in its long-term profitability. The biotech sector’s typical volatile cash flows and high-growth trajectories further contextualize the market’s positive reaction to these forward-looking projections.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet